NI202000058A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents

Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Info

Publication number
NI202000058A
NI202000058A NI202000058A NI202000058A NI202000058A NI 202000058 A NI202000058 A NI 202000058A NI 202000058 A NI202000058 A NI 202000058A NI 202000058 A NI202000058 A NI 202000058A NI 202000058 A NI202000058 A NI 202000058A
Authority
NI
Nicaragua
Prior art keywords
stimulator
cyclopentane
interferon genes
sting modulators
sting
Prior art date
Application number
NI202000058A
Other languages
English (en)
Inventor
James Wythes Martin
James Mcalpine Indrawan
Patman Ryan
Yuanjin Rui Eugene
Fensome Andrew
Maderna Andreas
Jalaie Mehran
S Gajiwala Ketan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NI202000058A publication Critical patent/NI202000058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Abstract

Compuesto de la fórmula general (I): o una sal farmacéuticamente aceptable del mismo, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos, y los usos de estos compuestos.
NI202000058A 2018-03-15 2020-08-28 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano NI202000058A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25

Publications (1)

Publication Number Publication Date
NI202000058A true NI202000058A (es) 2021-01-08

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000058A NI202000058A (es) 2018-03-15 2020-08-28 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Country Status (24)

Country Link
US (4) US10538542B2 (es)
EP (1) EP3765474B1 (es)
JP (1) JP7266942B2 (es)
KR (1) KR20200131878A (es)
CN (1) CN111918871A (es)
AU (1) AU2019234043A1 (es)
BR (1) BR112020018593A2 (es)
CA (1) CA3093631C (es)
CL (1) CL2020002352A1 (es)
CR (1) CR20200382A (es)
DO (1) DOP2020000160A (es)
EC (1) ECSP20057847A (es)
ES (1) ES2923298T3 (es)
IL (1) IL277278A (es)
MA (1) MA52012A (es)
MX (1) MX2020009587A (es)
NI (1) NI202000058A (es)
PE (1) PE20210412A1 (es)
PH (1) PH12020551486A1 (es)
RU (1) RU2020130048A (es)
SG (1) SG11202008102VA (es)
TW (1) TWI741268B (es)
UY (1) UY38145A (es)
WO (1) WO2019175776A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111954675A (zh) 2018-04-06 2020-11-17 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
KR20220070254A (ko) * 2019-09-25 2022-05-30 화이자 인코포레이티드 Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
MX2016015928A (es) * 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
CA3093631A1 (en) 2019-09-19
RU2020130048A3 (es) 2022-04-15
BR112020018593A2 (pt) 2020-12-29
US10968242B2 (en) 2021-04-06
US20230382932A1 (en) 2023-11-30
PH12020551486A1 (en) 2021-08-23
KR20200131878A (ko) 2020-11-24
JP7266942B2 (ja) 2023-05-01
ECSP20057847A (es) 2021-04-29
TW201945036A (zh) 2019-12-01
EP3765474B1 (en) 2022-06-15
US10538542B2 (en) 2020-01-21
WO2019175776A1 (en) 2019-09-19
CN111918871A (zh) 2020-11-10
EP3765474A1 (en) 2021-01-20
MX2020009587A (es) 2020-10-05
TWI741268B (zh) 2021-10-01
US20200102334A1 (en) 2020-04-02
UY38145A (es) 2019-10-31
CA3093631C (en) 2023-01-24
DOP2020000160A (es) 2020-09-30
RU2020130048A (ru) 2022-04-15
ES2923298T3 (es) 2022-09-26
SG11202008102VA (en) 2020-09-29
US20210230196A1 (en) 2021-07-29
US20190284216A1 (en) 2019-09-19
CR20200382A (es) 2020-12-10
CL2020002352A1 (es) 2020-12-18
AU2019234043A1 (en) 2020-09-17
IL277278A (en) 2020-10-29
JP2021518335A (ja) 2021-08-02
PE20210412A1 (es) 2021-03-04
MA52012A (fr) 2021-01-20

Similar Documents

Publication Publication Date Title
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2020001220A2 (es) Compuestos, composiciones y métodos
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2021002104A1 (es) Compuestos, composiciones y métodos.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CR20150454A (es) Compuestos amida para el tratamiento de vih
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
AR093705A1 (es) Depsipeptido y sus usos
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
EA202193015A1 (ru) Ингибиторы cdk
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
UY37941A (es) Derivados de bencimidazol y sus usos
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos
EA202091913A1 (ru) Модуляторы sting (стимулятора генов интерферона) на основе циклопентана
AR115865A2 (es) Compuestos terapéuticos